Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | CPS1 | P31327 | 3/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042623 | 1.00 | FFAR1 (0.43) | FFAR1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL5040728 | 0.87 | PRKCZ (0.44) | FFAR1CPS1HSD17B10 | |
| SCHEMBL5040727 | 0.87 | PRKCZ (0.44) | FFAR1CPS1HSD17B10 | |
| SCHEMBL2347876 | 0.85 | PTGS2 (0.45) | AKR1C3AKR1C2PTGS1PTGS2MTNR1A | |
| SCHEMBL5038048 | 0.81 | PTGS2 (0.39) | FFAR1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL5041275 | 0.80 | LDHA (0.40) | FFAR1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL10351204 | 0.79 | MTNR1A (0.38) | AKR1C3AKR1C2PTGS1PTGS2MTNR1A | |
| SCHEMBL25379205 | 0.77 | PTGS2 (0.46) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL10318257 | 0.77 | PTGS2 (0.46) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL9159786 | 0.77 | CNR2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | FFAR1 1355/4885AKR1C3 2566/4885AKR1C2 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.